

Appl. No. 09/865,989
Amtd. dated September 10, 2003
Reply to Office Action of July 11, 2003

II. Amendments to the Claims


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-75. (Cancelled)

76. (Currently amended) An ApoA-I agonist compound comprising:

(i) an 18 to 22-residue peptide or peptide analogue which forms an amphipathic α -helix in the presence of lipids and which comprises formula (I):



or a pharmaceutically acceptable salt thereof, wherein

X_1 is Pro (P), Ala (A), Gly (G), Asn (N), Gln (Q) or D-pro (p);

X_2 is an aliphatic residue;

X_3 is Leu (L);

X_4 is an acidic residue;

X_5 is Leu (L) or Phe (F);

X_6 is Leu (L) or Phe (F);

X_7 is a basic residue;

X_8 is an acidic residue;

X_9 is Leu (L) or Trp (W);

X_{10} is Leu (L) or Trp (W);

X_{11} is an acidic residue or Asn (N);

X_{12} is an acidic residue;

X_{13} is Leu (L), Trp (W) or Phe (F);

X_{14} is a basic residue or Leu (L);

X_{15} is Gln (Q) or Asn (N);

X_{16} is a basic residue;

X_{17} is Leu (L);

X_{18} is a basic residue;

wherein at least one L-enantiomeric residue of [the peptide or peptide analogue]

formula (I) is [(a)] replaced with an identical D-enantiomeric residue;

Okay to
enter
JSE
9-22-2003